Figure 6. Chimeric antibodies targeting human BAFF-R elicited in vivo therapeutic effects against drug resistant B-cell tumors.

Bioluminescence images of mice challenged with luciferase-expressing tumors (A) Rituximab-insensitive JeKo-1-CD20-KO cells or (B) ibrutinib-resistant Z-138 cells followed by antibody treatments as in Figure 4. Control group mice received PBS, NK cells alone, or (A) rituximab (following antibody treatment in Figure 4A) or (B) ibrutinib (25mg/kg IP every other day on days 3–17). (C) Tumor-free and overall survival curves of the mice shown in (A) and (B), respectively. Tumor free rate and survival differences between experimental and all control groups were analyzed by log-rank test (** P<0.001). Data are representative of three independent experiments.